Is Fulgent Genetics, Inc. (FLGT) Halal?

NASDAQ Healthcare United States $487M
✗ NOT HALAL
Confidence: 90/100
Fulgent Genetics, Inc. (FLGT) is Not Halal under AAOIFI Standard 21. While the debt ratio of 1.7% is acceptable, the cash and interest-bearing securities ratio of 73.6% exceeds the 30% threshold. Fulgent Genetics, Inc. operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 1.7%
/ 30%
73.6%
/ 30%
20.1%
/ 30%
9.58%
/ 5%
✗ NOT HALAL
DJIM 1.7%
/ 33%
73.6%
/ 33%
20.1%
/ 33%
9.58%
/ 5%
✗ NOT HALAL
MSCI 0.6%
/ 33%
27.7%
/ 33%
7.5%
/ 33%
9.58%
/ 5%
✗ NOT HALAL
S&P 1.7%
/ 33%
73.6%
/ 33%
20.1%
/ 33%
9.58%
/ 5%
✗ NOT HALAL
FTSE 0.6%
/ 33%
27.7%
/ 33%
7.5%
/ 50%
9.58%
/ 5%
✗ NOT HALAL

Financial Highlights

EPS
$-1.97
P/B Ratio
0.4
EV/EBITDA
-2.4
EV: $154M
Revenue
$323M
Growth: 9.3%
Beta
1.0
Average volatility
Current Ratio
6.5

Profitability

Gross Margin 40.6%
Operating Margin -41.2%
Net Margin -18.8%
Return on Equity (ROE) -5.5%
Return on Assets (ROA) -4.6%

Cash Flow & Balance Sheet

Operating Cash Flow-$102M
Free Cash Flow-$124M
Total Debt$8M
Debt-to-Equity0.7
Current Ratio6.5
Total Assets$1.2B

Price & Trading

Last Close$16.38
50-Day MA$20.94
200-Day MA$22.66
Avg Volume445K
Beta1.0
52-Week Range
$13.46
$31.04

About Fulgent Genetics, Inc. (FLGT)

CEO
Mr. Ming Hsieh
Employees
1,315
Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Exchange
NASDAQ
Market Cap
$487M
Currency
USD

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, large corporations, and patients. Fulgent Genetics, Inc. was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is Fulgent Genetics, Inc. (FLGT) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), Fulgent Genetics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is Fulgent Genetics, Inc.'s debt ratio?

Fulgent Genetics, Inc.'s debt ratio is 1.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.6%.

What are Fulgent Genetics, Inc.'s key financial metrics?

Fulgent Genetics, Inc. has a market capitalization of $487M, and revenue of $323M. The company maintains a gross margin of 40.6% and a net margin of -18.8%. Return on equity stands at -5.5%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.